American Society of Hirudotherapy

Comparing survival with vitamin K antagonists, low-molecular-weight heparin, and direct oral anticoagulants in patients with cancer-a systematic review and meta-analysis

Research article published in Research and practice in thrombosis and haemostasis (2025)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Research reportClinical LiteratureXirou V et al. · Research and practice in thrombosis and haemostasis, 2026

Abstract

BACKGROUND: Venous thromboembolism (VTE) is a frequent complication in malignancy. Low-molecular-weight heparins and direct oral anticoagulants have replaced vitamin K antagonists (VKAs) as the standard of care for cancer-associated VTE. Nonetheless, clinical trials have not established a survival benefit of these agents compared with VKA. OBJECTIVES: We conducted a systematic review and meta-analysis to compare survival in cancer patients receiving VKA vs other anticoagulants. METHODS: We searched Embase, Web of Science, PubMed, ClinicalTrials.gov, and Cochrane from inception until April 10, 2025, focusing on the use of VKA and non-VKA in cancer patients. Primary outcome was mortality and secondary outcomes included thromboembolism and bleeding. RESULTS: Of 11,198 studies screened, 14 studies (70,025 patients) were included. VKA were associated with lower mortality than non-VKA in observational studies (odds ratio [OR], 0.84; 95% CI, 0.78-0.91; I 2 = 81%; n = 6 studies) but not in randomized controlled trials (OR, 0.99; 95% CI, 0.86-1.13; I 2 = 0%; n = 8 studies). In subgroup analysis, follow-up period of >6 months (OR, 0.85; 95% CI, 0.79-0.92; I 2 = 75%), solid malignancies (OR, 0.81; 95% CI, 0.75-0.88; I 2 = 78%), and indication of VTE only (OR, 0.89; 95% CI, 0.83-0.96; I 2 = 42%) demonstrated improved survival with VKA. CONCLUSION: The use of VKA was associated with lower mortality than non-VKA anticoagulation in patients with cancer in observational studies but not in randomized trials. The analysis was limited by high heterogeneity, which must be considered when interpreting results.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Summary

Pooling 14 studies (70,025 patients) with cancer, vitamin K antagonists were associated with lower mortality than other anticoagulants in observational studies (OR 0.84) but not in randomized trials (OR 0.99); high heterogeneity limits interpretation.

Context

This systematic review and meta-analysis (14 studies, 70,025 cancer patients) compared survival across vitamin K antagonists, low-molecular-weight heparin, and direct oral anticoagulants for cancer-associated venous thromboembolism, finding lower mortality with VKAs in observational studies (OR 0.84) but no survival difference in randomized trials (OR 0.99). It documents how different anticoagulant classes are weighed in a thrombosis-prone population, the broad antithrombotic-management context within which the medicinal-leech secretome's natural anticoagulants are positioned. Honest caveat: the authors note high heterogeneity and a clear split between observational and randomized findings, so the apparent VKA benefit is not confirmed by RCTs; the analysis concerns systemic anticoagulant drugs and includes no data on, or mention of, leeches or hirudotherapy.

Citation

Reference (Vancouver style)

Xirou V, Patel A, Altamirano MFA, Singh R, Gusdorf J, Barnum K, et al. Comparing survival with vitamin K antagonists, low-molecular-weight heparin, and direct oral anticoagulants in patients with cancer-a systematic review and meta-analysis. Res Pract Thromb Haemost. 2026;10(1):103268. doi:10.1016/j.rpth.2025.103268. PMID: 41560781

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.